01/10/2014
Report no. 5/2014
Amendment to a significant contract in the subsidiary company “Lubmed" sp. z o.o. in Lubin
Pursuant to §5 (1) (3) of the Regulation of the Minister of Finance of 19 February 2009 on current and periodic information provided by issuers of securities, the Management Board of EMC Instytut Medyczny S.A. announces that:
- on 10 January 2014 the Company received an annex to the contract concluded by the
subsidiary company “Lubmed” sp. z o.o. with the National Health Fund - the Dolnośląskie Voivodeship Branch in Wrocław (the Fund Branch) concerning the provision of healthcare services in the scope of outpatient specialist care for the period 1 January to 31 December 2013, and
-medical services, which were rendered under the contract for the provision of healthcare services such as primary healthcare for the period 1 January to 31 December 2013, have been settled.
Healthcare services referred to hereinabove are provided by the subsidiary company “Lubmed” Sp. z o.o. in Lubin owned by EMC Instytut Medyczny S.A.
The Issuer informed about the contracts concerning services rendered in 2013 in its current reports nos. 12/2013 of 31.01.2013 and 22/2013 of 21.02.2013.
Having settled the contract for providing healthcare services such as primary healthcare in the period 1 January to 31 December 2013, the Fund Branch liability towards the subsidiary company therefrom is PLN 5,962,039.46 exceeding earlier estimate by PLN 131,299.46.
As a result of making the above correction and signing the said annex to the contract concerning the provision of healthcare services in the scope of outpatient specialist care, the total maximum Fund Branch liability towards three Outpatient Clinics owned by the subsidiary company “Lubmed” Sp. z o.o. in Lubin currently amounts to PLN 8,555,159.51 (an increase by PLN 137,647.46) in the period 1 January to 31 December 2013.
The other material terms of the contract with the highest value made public remain unchanged.
A criterion for a contract to be considered significant:
The value of contracts exceeds 10% of the Issuer’s equity capital.